Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
Article | IMSEAR | ID: sea-194022

ABSTRACT

Background: PSA levels between 0-4 ng/ml is generally accepted as normal range, there is no world widely accepted cut-off value. PSA level is most commonly used for determining patients to whom needle biopsy should be performed. Authors aimed to investigate the relationship between preoperative PSA level and histopathological features.Methods: Ninety prostatic adenocarcinoma cases diagnosed between January 2013 and January 2018 and treated by RP were included. Patients had no measurement of PSA before the operation were excluded from the study. Patients were grouped according to preoperative PSA as low-risk (<10 ng/ml), medium-risk (10-20 ng/ml) and high-risk (>20 ng/ml). The relations between all of the histopathological parameters were analyzed in addition to the preoperative PSA levels.Results: The mean age and preoperative PSA level was found as 64.16, and 12.33, respectively. The presence of EPE and tumour positive base margin showed significant relation among PSA groups as well as the presence of lymphovascular invasion and the involvement of the seminal vesicles. Intracytoplasmic mucin and foamy cytoplasm was more common in low-risk PSA group and the difference was significant.Conclusions: PSA level is one of the most commonly used marker for predicting high risk patients before the operation however it may also show relation with various histopathological factors that have effect on the prognosis of prostatic adenocarcinoma.

2.
An. bras. dermatol ; 92(5,supl.1): 59-61, 2017. tab, graf
Article in English | LILACS | ID: biblio-887080

ABSTRACT

Abstract Deferasirox is an iron chelator agent used in the treatment of diseases with iron overload, such as thalassemia and myelodysplastic syndrome. Although the majority of adverse reactions of deferasirox involve gastrointestinal symptoms and increase in serum creatinine and transaminases, skin rashes, such as maculopapular and urticarial eruptions, have also been reported. This study reports a case of myelodysplastic syndrome with urticarial vasculitis due to deferasirox therapy. Drug eruption was been confirmed by means of a challenge test, together with histopathological and clinical findings. To the best of our knowledge, we report the first case of deferasirox-induced urticarial vasculitis. Physicians should be aware of the possibility of urticarial vasculitis on deferasirox therapy and the fact that the discontinuation of the drug generally results in improvement.


Subject(s)
Humans , Female , Aged , Triazoles/adverse effects , Urticaria/chemically induced , Vasculitis/chemically induced , Benzoates/adverse effects , Myelodysplastic Syndromes/drug therapy , Iron Chelating Agents/adverse effects , Drug Eruptions/etiology , Urticaria/pathology , Vasculitis/pathology , Biopsy , Drug Eruptions/pathology
3.
An. bras. dermatol ; 92(5,supl.1): 21-23, 2017. graf
Article in English | LILACS | ID: biblio-887101

ABSTRACT

Abstract: Amyloidosis cutis dyschromica is a rare type of primary cutaneous amyloidosis characterized by reticulate hyper-pigmentation with discrete hypopigmented macules. Up to date, about 50 cases of amyloidosis cutis dyschromica have been reported and the majority are familial cases of Asian ethnicity. Various diseases, particularly autoimmune diseases such as systemic sclerosis and systemic lupus erythematosus, have been associated with amyloidosis cutis dyschromica. Herein, we report a case of amyloidosis cutis dyschromica accompanying familial Mediterranean fever with a delayed diagnosis of 40 years. To the best of our knowledge, this is the first report of the association of amyloidosis cutis dyschromica and familial mediterranean fever.


Subject(s)
Humans , Female , Middle Aged , Familial Mediterranean Fever/complications , Skin Diseases, Genetic/complications , Skin Diseases, Genetic/pathology , Amyloidosis, Familial/complications , Amyloidosis, Familial/pathology , Biopsy , Hyperpigmentation/pathology , Dermis/pathology
4.
Indian J Pathol Microbiol ; 2014 Jul-sept 57 (3): 396-399
Article in English | IMSEAR | ID: sea-156071

ABSTRACT

Background: Bone marrow biopsy is widely used method for diagnosis, followup and staging of hemato-oncologic diseases. This procedure is also used for determining the bone marrow metastasis in patients with solid tumors. In this study, clinical, hematological, and pathological features of 58 patients with bone marrow metastases diagnosed by bone marrow biopsies were examined retrospectively Materials and Methods: Among 3345 bone marrow biopsies performed in our hospital between January 2006 and August 2013, 58 cases with solid tumor metastasized to bone marrow were included in this study. Results: Among 58 cases with solid organ carcinoma metastasis in bone marrow, mean age was 59.9. Thirty-nine cases were found to have a known primary tumor focus. The most common tumors metastasized to bone marrow were breast carcinomas (23 patients, 59%), gastric carcinomas (6 patients, 15.3%), prostate carcinomas (4 patients, 10,2%), and lung carcinomas (3 patients, 7.7%), respectively. Nineteen patients were firstly diagnosed from bone marrow biopsies as metastatic carcinomas. The median overall survival after bone marrow metastasis was 28 days (95% confidence interval: 7.5-48.4). The median overall survival difference was not statistically significant between patients with primary known and unknown tumor (P = 0.973). Statistically significant difference was observed between the survival of breast cancer and gastric cancer (P = 0.028). The most common hematologic symptom was the coexistence of anemia and thrombocytopenia (31%), thrombocytopenia (27.6%) and anemia (20.7%) alone. The median overall survival difference was statistically significant between patients who have anemia and thrombocytopenia (P < 0.005). Conclusion: Bone marrow biopsy is an easily accessible, easily applied, a useful procedure for diagnosing metastatic diseases in patients with hematologic symptoms such as anemia and thrombocytopenia besides being an uncomfortable procedure for patients. Furthermore, it is useful in predicting the prognosis and short survey after diagnosing bone marrow metastasis.

5.
Indian J Pathol Microbiol ; 2011 Apr-Jun 54(2): 355-358
Article in English | IMSEAR | ID: sea-141986

ABSTRACT

Background: Hepatitis B virus (HBV) is a potentially life-threatening liver infection which may progress to liver failure and cirrhosis. Intrahepatic expression patterns of viral antigens detected by immunohistochemistry may have prognostic implications in disease process. Aim: In this study, we aimed to investigate the relationship between the HBV core antigen (HBcAg) expression and histological activity index (HAI), fibrosis, serum hepatitis B e-antigen (HBeAg) status and HBV DNA levels in patients with chronic HBV infection. Materials and Methods: A total of 114 liver biopsies from patients with chronic HBV infection were included in the study. Immunohistochemical expression of HBcAg and its relation with HAI, fibrosis, serum alanine aminotransferase (ALT) levels, HBeAg status and HBV DNA levels were assessed. Results: The presence of nuclear expression of HBcAg did not show any correlations with ALT levels, HAI and fibrosis score. When the groups were categorized according to the HBeAg status, nuclear HBcAg expression was found to be high in HBeAg positive patients. However, HBcAg nuclear expression showed significant correlations with HBV DNA levels and fibrosis scores in HBeAg negative but not HBeAg positive patients. HBV DNA levels were also significantly associated with HAI and fibrosis scores in HBeAg negative patients. Conclusions: Significant differences found between HBeAg positive and negative patients suggest that HBeAg negative disease is different from HBeAg positive disease, and also point outs that in HBeAg negative disease, patients with nuclear HBcAg expression and increased levels of HBV DNA levels are at a higher risk of developing progressive liver disease.


Subject(s)
Adult , Aged , Aged, 80 and over , Alanine Transaminase/blood , Biopsy , DNA, Viral/blood , Female , Gene Expression , Hepatitis B Core Antigens/biosynthesis , Hepatitis B e Antigens/blood , Hepatitis B, Chronic/pathology , Humans , Immunohistochemistry , Liver/pathology , Liver Cirrhosis/pathology , Male , Microscopy , Middle Aged
SELECTION OF CITATIONS
SEARCH DETAIL